Ingrezza, Austedo or Tetrabenazine for Huntington's Chorea, and Where the AMT-130 Gene Therapy Stands Now

Since tetrabenazine was approved in 2008, every Huntington's drug the FDA has cleared does the same job: it quiets chorea, the jerking, dance-like movements that get in the way of eating, walking and sleeping, without touching the disease underneath. Three pills do that today: Ingrezza (valbenazine), Austedo (deutetrabenazine) and tetrabenazine, sold as Xenazine and as cheaper generics. On September 2, 2026, for the first time, a company asked the FDA to approve a treatment meant to slow Huntington's itself: uniQure's AMT-130 gene therapy, whose 4-year results arrived 4 weeks later and complicated the story. This guide starts with the choice families face today, between 3 pills that differ in dosing, generics, Medicare coverage and drugmaker help, and ends with where that first disease-slowing attempt actually stands.

Huntington's disease affects about 41,000 Americans with symptoms, and more than 200,000 more are at risk of inheriting it, according to the Huntington's Disease Society of America. Each child of a parent with the disease has a 50% chance of carrying the gene. Chorea is often the most visible symptom, though families who met with the FDA in 2015 and again in 2024 described changes in mood, behavior and thinking as major burdens alongside the movements, and no approved medicine yet changes the course of the disease itself (FDA, 2016; HDSA, 2025).

What Ingrezza, Austedo and Tetrabenazine Have in Common for Huntington's Chorea

Ingrezza, Austedo and tetrabenazine belong to a drug family called VMAT2 inhibitors. They reduce the amount of dopamine released inside the brain's movement circuits, which quiets the extra movements of chorea. Tetrabenazine came first, approved in August 2008. Austedo, a modified version of tetrabenazine that the body breaks down more slowly, was approved for Huntington's chorea in April 2017. Ingrezza, first approved for a different movement disorder called tardive dyskinesia, added Huntington's chorea in August 2023 (Drugs@FDA).

Families describe the tradeoff plainly. In the Huntington's Disease Society of America's August 2025 Voice of the Patient report, built on a November 2024 meeting between Huntington's families and the FDA and a 2024 community survey, 13.2% of early-stage and 28.9% of mid-stage respondents said they take a VMAT2 inhibitor. The report notes that medicines that help chorea can lead to thinking problems or other side effects over time, and more than 55% of early and mid-stage respondents said they adjust their medicines with their doctors to keep side effects down (HDSA, 2025). The pattern is not new. At the FDA's first Huntington's meeting in 2015, caregivers said tetrabenazine helped loved ones stay independent longer, while others described depression, trouble sleeping and a flattening of personality (FDA, 2016).

“There's not one medication that's going to suit everybody.”

A person living with Huntington's disease, quoted in HDSA's Voice of the Patient report, August 2025

Beyond the boxed warning, their labels list the same family of side effects: sleepiness, restlessness, stiffness and slowness that can look like Parkinson's disease, and a change in heart rhythm on an ECG known as QT prolongation. Austedo and tetrabenazine must not be used by someone who is suicidal or whose depression is untreated or not well treated. Ingrezza's label carries the same warning without that specific restriction. A neurologist who knows Huntington's disease usually weighs how much the chorea matters to daily life against mood, sleep and swallowing before choosing.

Ingrezza dosing for Huntington's chorea

The Huntington's schedule is slower than the one many websites quote, which is for tardive dyskinesia. For Huntington's chorea, the label starts Ingrezza at 40 mg once a day and raises it by 20 mg every 2 weeks to the recommended 80 mg, with 40 or 60 mg an option depending on how a person responds. People known to be CYP2D6 poor metabolizers, meaning their bodies clear the drug slowly, and people with moderate or severe liver problems stay at 40 mg. The capsules can be taken with or without food.

Austedo and Austedo XR dosing

Austedo XR is a once-daily tablet that starts at 12 mg and can go up by 6 mg each week to a maximum of 48 mg a day. The original Austedo tablets reach the same doses as 2 doses a day, taken with food. For poor CYP2D6 metabolizers or people taking strong CYP2D6-blocking medicines, such as some antidepressants, the maximum is 36 mg a day. Someone switching from tetrabenazine stops it and starts Austedo the next day at a dose from the label's conversion table.

Tetrabenazine dosing and the CYP2D6 test

Tetrabenazine needs the most hands-on dosing. It starts at 12.5 mg each morning, moves to 12.5 mg twice a day in week 2, then rises by 12.5 mg a week. Doses of 37.5 to 50 mg a day are split into 3, with no single dose above 25 mg. It is the only one of the 3 whose label requires a CYP2D6 gene test, before going above 50 mg a day. People who clear it normally can reach 100 mg a day, while poor metabolizers stop at 50 mg.

What the Huntington's Chorea Trials Showed for Each Drug

Each drug worked clearly better than placebo, and all 3 effects faded once the drug stopped: Ingrezza's label reports chorea scores back to baseline 2 weeks after the last dose, and Austedo's after 1 week. The patient-rated results tell the same story. In KINECT-HD, 53% of people on Ingrezza rated themselves much or very much improved, against 26% on placebo, and in First-HD the figures were 51% against 20% (FDA labels). Because no trial has put 2 of these drugs head to head, nobody can say from this data that one controls chorea better than another.

The mood signal showed up in the trials too. In the 2006 tetrabenazine study, 19% of people on the drug had depression or worsening depression, against none on placebo, and in First-HD 2% on Austedo reported suicidal thoughts, against none on placebo (FDA labels). Huntington's disease itself raises the risk of depression and suicide, which is why every label asks doctors to watch closely and why families are often the first to notice a change.

Is There a Generic Ingrezza or Austedo?

When the trials cannot separate the 3 drugs, price often does, and the first question families type is whether Ingrezza comes as a generic. Not one you can buy yet. The FDA approved Lupin's generic valbenazine on April 5, 2024, and Zydus's in August 2024, but neither is on sale, and the FDA now lists Zydus's version as discontinued (Drugs@FDA). Neurocrine settled its patent cases with 4 generic makers, allowing them to sell from March 1, 2038, or earlier in certain customary circumstances, according to the company's November 2023 announcement. A generic of the twice-daily Austedo tablets from Aurobindo was approved in December 2024 and is also listed as discontinued, and Teva's 2022 settlement with Aurobindo allows sales from April 2033 or earlier. There is no generic of Austedo XR.

Tetrabenazine is the exception. It has been available as a generic from several manufacturers for years, and it is approved for exactly the same use, Huntington's chorea. In a July 2026 price list Neurocrine published for Vermont prescribers, most generic tetrabenazine 12.5 mg listed at about $8,800 for 112 tablets, 2 makers listed at $1,758 and $239, and brand Xenazine at $25,523. These are average wholesale prices, list figures that few people actually pay, but the spread between makers is a reason to ask your pharmacy which generic it stocks and what your plan charges for it.

Ingrezza and Austedo Cost, Medicare and Help Paying

Austedo and Austedo XR were among the 15 drugs in the second round of Medicare drug price negotiation. The price CMS published in November 2025 is $4,093 for a 30-day supply, 38% below the 2024 list price of $6,623, and it takes effect on January 1, 2027 (CMS). Ingrezza has not been selected in any round. Neurocrine's 2025 annual report says CMS confirmed in January 2025 that Ingrezza qualifies for the small biotech exception, which keeps it out of negotiation for now.

Price is only part of the access problem. In HDSA's 2025 report, families described insurance changes that forced them to switch care centers, mail-order deliveries that arrived late and local pharmacies that do not stock Huntington's medicines. For a person on Medicare, the yearly cap on what you pay for Part D drugs matters more than the list price. It is $2,100 in 2026 and $2,400 in 2027 (CMS and Medicare.gov). Medicare open enrollment runs from October 15th to December 7th every year, and it is the moment to check that your 2027 plan covers the chorea drug you take and what prior authorization it needs. Our Medicare open enrollment guide walks through those checks.

The drugmakers' copay cards work only with commercial insurance. Neurocrine's program for Ingrezza offers a $0 copay card for commercially insured patients, a free 30-day trial for new patients and a free-drug program for people who are uninsured, lack coverage for Ingrezza or show financial need (Neurocrine, 1-844-647-3992). Its public page does not say whether people on Medicare can use the free-drug program, so ask directly. Teva Total Support offers an Austedo copay card that excludes Medicare, Medicaid and other government insurance, plus a free 30-day trial voucher (Teva, 1-800-887-8100). Lundbeck's Xenazine copay program has similar exclusions. The Ingrezza, Austedo and tetrabenazine pages list each program and who qualifies, and the patient assistance finder adds charity funds.

Where the AMT-130 Gene Therapy for Huntington's Disease Stands

Everything above treats a symptom, and in the trials the benefit was gone within 1 to 2 weeks of the last dose. AMT-130, now called ifezuntirgene inilparvovec, is built on a different premise: a one-time gene therapy from uniQure meant to work for years. It is delivered by neurosurgery, an MRI-guided infusion directly into the caudate and putamen, the brain regions Huntington's damages first, and it is designed to lower production of the huntingtin protein. Its path to the FDA has changed direction several times.

What the 3-year and 4-year AMT-130 results showed

Every AMT-130 efficacy number compares a small group of treated patients with people followed in Enroll-HD, a large natural-history study, rather than with a placebo group. In September 2025, uniQure reported that among 12 high-dose patients followed for 3 years, decline on the cUHDRS, a combined score of movement, thinking and daily function, was 75% slower than in matched Enroll-HD participants (uniQure, September 2025). That 3-year analysis is what the FDA filing rests on.

On September 29, 2026, uniQure released 4-year results that were not part of the filing. At 48 months, with 12 high-dose patients, the cUHDRS showed 44% slower decline, a result that did not reach statistical significance (p=0.144); this was the pre-specified main measure for that time point. Total Functional Capacity, a score of work, chores and self-care, showed 61% slower decline. An updated 3-year analysis that added 3 more high-dose patients showed 80% slower decline on the cUHDRS (uniQure, September 2026). The company said 53% of the comparison group's 48-month data were missing and that its own analysis suggested this understated the effect, and its release notes that the percentage slowing depends on how fast the comparison group declined. Independent researchers have not yet reviewed these numbers in a published paper.

On safety, uniQure reports that 5 high-dose participants, or 17%, had a serious treatment-related side effect involving inflammation in the brain or spinal cord, and all fully resolved. One low-dose patient died by suicide about 5 years after treatment, which the study investigator judged unrelated to the therapy (uniQure, September 2026). As the company's release notes, suicidal thoughts and suicide occur at much higher rates in Huntington's disease than in the general population.

What the FDA's filing decision means for families

The next step is administrative but meaningful. Within 60 days of a submission, the FDA decides whether an application is complete enough to review. If it accepts AMT-130 with the priority review uniQure requested, the FDA's standard goal for a decision would be about 8 months after submission, which would point to around May 2027. Acceptance is not approval, and the FDA can also refuse to file an application. According to uniQure, the FDA wants a confirmatory study well underway, and potentially fully enrolled, by the time of any accelerated approval, and that study had not been posted on ClinicalTrials.gov as of October 11, 2026. The 2 existing AMT-130 trials are not enrolling. The AMT-130 decision page will carry the filing decision when it is announced.

Huntington's Disease Clinical Trials You Can Join Now

AMT-130 is the first disease-slowing treatment to reach the FDA, but it is not the only attempt, and most of the trials open today are chasing the same goal with a pill instead of brain surgery. Several have changed course in 2026. Roche stopped its tominersen program, GENERATION HD2, on July 9, 2026 after it lowered huntingtin but missed its efficacy goal, according to the company's letter to the Huntington's community. These 4 were recruiting on ClinicalTrials.gov on October 11, 2026.

The Huntington's disease trials page lists every open study with its sites and eligibility, and it has a sign-up for an email when the FDA acts on AMT-130 or a new trial opens. Some studies enroll people who carry the gene before symptoms start, such as an Australian trial of N-acetylcysteine for gene carriers expected to develop symptoms within 10 years (NCT05509153).

Questions Families Ask About Huntington's Chorea Medicines